PhD in Chemical Engineering, University of Cambridge, UK, Master of Chemical Engineering, Tsinghua University.

He is currently the chairman and chief scientist of Shenzhen Resproly Biopharmaceutical Co., Ltd., and a member of the Inhalation Particle Professional Committee of the Chinese Society of Particles.

Dr. Chen used to be a pharmaceutical expert of Vectura in the United Kingdom. He has more than 15 years of inhalation drug research and development and industry experience. He is the head of the research and development of many international blockbuster drugs. Among the 17 products that have been marketed, there are 13 mainstream varieties. Ph.Ds have successful development experience, including GSK's latest Ellipta® series, and have successfully approved and authorized cases in the European Union and the United States. Especially the successful experience of inhalation of high-end complex preparations of Symbico® and Seretide®. Among them, Symbico's generic drug AirBuFo® is currently the only generic drug approved for marketing in the EU, and Seretide® generic drug is currently the only EU And FDA both approved generic drugs for marketing. Dr. Chen has published more than 30 articles in world-class professional magazines, periodicals, conferences, and applied for more than 20 domestic and foreign patents including China, the United States, and PCT. After returning to China, Dr. Chen devoted himself to the R&D and production of inhaled aerosols and inhaled powders for respiratory diseases, focusing on the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary hypertension, and hypertension. R&D and production of dry powder inhalation administration for pathogenic sudden influenza, especially anti-coronavirus drugs. It was launched in response to the current situation that my country is far behind the level of inhalation drug development and production in developed countries.